Diagnosis and treatment of acute coronary syndromes: a review

DL Bhatt, RD Lopes, RA Harrington - Jama, 2022 - jamanetwork.com
Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

2018 ESC/EACTS Guidelines on myocardial revascularization

M Sousa-Uva, FJ Neumann, A Ahlsson… - European Journal of …, 2019 - academic.oup.com
These Guidelines represent the third time that the ESC and EACTS have brought together
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …

[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention

DJ Angiolillo, M Galli, JP Collet, A Kastrati… - …, 2022 - ncbi.nlm.nih.gov
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

2018 ESC/EACTS Guidelines on myocardial revascularization

FJ Neumann, M Sousa-Uva, A Ahlsson… - European heart …, 2019 - academic.oup.com
always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …

[HTML][HTML] Ticagrelor with or without aspirin in high-risk patients after PCI

R Mehran, U Baber, SK Sharma… - … England Journal of …, 2019 - Mass Medical Soc
Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin …

P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg… - The Lancet, 2018 - thelancet.com
Background We hypothesised that ticagrelor, in combination with aspirin for 1 month,
followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention …

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy …

M Valgimigli, H Bueno, RA Byrne, JP Collet… - European heart …, 2018 - academic.oup.com
Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High …

P Urban, R Mehran, R Colleran, DJ Angiolillo… - Circulation, 2019 - Am Heart Assoc
Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …

JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome

K Kimura, T Kimura, M Ishihara, Y Nakagawa… - Circulation …, 2019 - jstage.jst.go.jp
Acute coronary syndromes (ACS) are a comprehensive disease concept characterized by
acute myocardial ischemia caused by disruption of coronary artery plaque and consequent …

Bleeding avoidance strategies in percutaneous coronary intervention

D Capodanno, DL Bhatt, CM Gibson, S James… - Nature Reviews …, 2022 - nature.com
For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …